Form 4: Director Lee Newcomer Receives Myriad Genetics Equity Grant

Director Lee Nisley Newcomer was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Summary

• Director Lee Nisley Newcomer acquired 59,701 restricted stock units (RSUs) of Myriad Genetics, Inc. (MYGN) common stock.
• The transaction occurred on June 4, 2026, at a price of $0 per share as part of an equity incentive grant.
• Following this transaction, the reporting person's total beneficial ownership of common stock increased to 191,842 shares.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board of directors.

Negatives

• None identified in this filing.

Risks

• Vesting of equity is subject to time-based conditions which may be impacted by future corporate events or board tenure.

Future Outlook

The RSUs represent a contingent right to receive common stock, vesting on the earlier of the first anniversary of the grant or the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align leadership incentives with long-term shareholder value creation in the biotechnology sector.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for publicly traded companies in the healthcare and biotech industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment between director interests and company performance.

Next Steps

• Vesting of the 59,701 restricted stock units on the earlier of June 4, 2027, or the date of the next annual meeting of stockholders.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation